Grant: Operating Grant: Industry-partnered Collaborative Research - Rx&D partner
University of Alberta
$175,000.00
Studies on modulation of the innate immune response to HCV in chimeric mice
EF 2008-09
Résumé
Hepatitis C Virus (HCV) is a major cause of liver disease with an estimated 250,000 HCV carriers in Canada and 170 million worldwide. Approximately 80% of HCV-infected people develop a chronic infection. The 20% of patients that clear the virus likely do so through two branches of the immune system - the innate and the adaptive immune systems.
In this study, Dr. Tyrrell will collaborate with the pharmaceutical company, GlaxoSmithKline, to study ways to enhance the strength of the innate immune response to eliminate HCV in an animal model of HCV infection. These studies may lead to improved therapy for chronic carriers of HCV.
Programme
Operating Grant: Industry-partnered Collaborative Research - Rx&D partner
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
182371
Name
Tyrrell D. Lorne J
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
GlaxoSmithKline (Mississauga, Ontario); GlaxoSmithKline (Mississauga, Ontario)
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Industry Partnered Collaborative Research
Projecttitle
Studies on modulation of the innate immune response to HCV in chimeric mice
Programtype2
Operating Grants
Orgnameinp2
University of Alberta
Cihramount2
$175,000
Cihrequipment2
$0
Programname2
Operating Grant: Industry-partnered Collaborative Research - Rx&D partner
Keyworddelim
Animal Model; Hepatitis C Virus; Modulators Of Innate Immune Response
Abstract
Hepatitis C Virus (HCV) is a major cause of liver disease with an estimated 250,000 HCV carriers in Canada and 170 million worldwide. Approximately 80% of HCV-infected people develop a chronic infection. The 20% of patients that clear the virus likely do so through two branches of the immune system - the innate and the adaptive immune systems.
In this study, Dr. Tyrrell will collaborate with the pharmaceutical company, GlaxoSmithKline, to study ways to enhance the strength of the innate immune response to eliminate HCV in an animal model of HCV infection. These studies may lead to improved therapy for chronic carriers of HCV.
Competitiondate
200903
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Tyrrell, D. Lorne J
Approvedterm
2 ans 0 mois
Cihrcontribution2
Patient Oriented Research~ $175,000~ $0~
